Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTYCILE)

• DTT Name: Vasopressin receptor (VR)
• Synonyms: Human vasopressin receptor
• Gene Name: VR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T04394

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[1]

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 86-8050	DM31RQS	Heart failure	BD10-BD13	Phase 1	[2]
BR6819	DMOQ2GB	Heart failure	BD10-BD13	Phase 1	[3]
SKF-105494	DMG7XKP	Diuretic vasodilator	BA00	Phase 1	[4]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
F-992	DMJ3MAZ	Urinary incontinence	MF50.2	Terminated	[5]

References

• [1] Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.
• [2] WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6.
• [5] A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.. Mol Cell Biol. 1992 January; 12(1): 128-135.